⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for ovarian clear cell adenocarcinoma

Every month we try and update this database with for ovarian clear cell adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer SurvivorsNCT03641287
Ovarian Cancer
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Ovari...
Ovarian Adenoca...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Primary Periton...
Primary Periton...
Exercise Counse...
Aerobic Exercis...
Physiological S...
Quality-of-Life...
Questionnaire A...
Best Practice
18 Years - University of Washington
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT00719303
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Ovari...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Primary Periton...
Stage IIA Fallo...
Stage IIA Ovari...
Stage IIB Fallo...
Stage IIB Ovari...
Stage IIC Fallo...
Stage IIC Ovari...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Undifferentiate...
Undifferentiate...
Behavioral Diet...
Compliance Moni...
Counseling
Educational Int...
Exercise Interv...
Laboratory Biom...
Quality-of-Life...
Questionnaire A...
18 Years - GOG Foundation
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerNCT01074411
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Serous ...
Ovarian Transit...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Undifferentiate...
Undifferentiate...
Bortezomib
Carboplatin
Laboratory Biom...
Pharmacological...
18 Years - National Cancer Institute (NCI)
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT02446600
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Prima...
Biospecimen Col...
Carboplatin
Cediranib Malea...
Computed Tomogr...
Echocardiograph...
Gemcitabine
Gemcitabine Hyd...
Laboratory Biom...
Magnetic Resona...
Multigated Acqu...
Olaparib
Paclitaxel
Pegylated Lipos...
Pharmacological...
Quality-of-Life...
18 Years - National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian CancerNCT00979992
Ovarian Clear C...
Recurrent Ovari...
Laboratory Biom...
Sunitinib Malat...
18 Years - National Cancer Institute (NCI)
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerNCT00989651
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Brenner...
Ovarian Carcino...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Primary Periton...
Stage IIA Fallo...
Stage IIA Ovari...
Stage IIB Fallo...
Stage IIB Ovari...
Stage IIC Fallo...
Stage IIC Ovari...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Bevacizumab
Carboplatin
Cisplatin
Laboratory Biom...
Paclitaxel
Veliparib
18 Years - National Cancer Institute (NCI)
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer SurvivorsNCT03641287
Ovarian Cancer
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Ovari...
Ovarian Adenoca...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Primary Periton...
Primary Periton...
Exercise Counse...
Aerobic Exercis...
Physiological S...
Quality-of-Life...
Questionnaire A...
Best Practice
18 Years - University of Washington
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersNCT03924245
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
High Grade Fall...
High Grade Ovar...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Primary Periton...
Recurrent Endom...
Recurrent Ovari...
Recurrent Prima...
Entinostat
Olaparib
18 Years - Vanderbilt-Ingram Cancer Center
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT02315430
Fallopian Tube ...
Ovarian Clear C...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Cabozantinib S-...
Laboratory Biom...
18 Years - National Cancer Institute (NCI)
AMT-151 in Patients With Selected Advanced Solid TumoursNCT05498597
Advanced Solid ...
Advanced Cancer
Advanced Carcin...
Ovarian Cancer
Ovarian Carcino...
Ovarian Epithel...
Ovarian Endomet...
Endometrial Can...
Endometrial Ade...
Endometrial Ser...
Endometrial End...
Endometrial Cle...
Lung Adenocarci...
Triple Negative...
Pancreatic Duct...
Malignant Pleur...
Ovarian Clear C...
Ovarian Clear C...
Ovarian Mucinou...
AMT-151
18 Years - Multitude Therapeutics Inc.
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerNCT01074411
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Serous ...
Ovarian Transit...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Undifferentiate...
Undifferentiate...
Bortezomib
Carboplatin
Laboratory Biom...
Pharmacological...
18 Years - National Cancer Institute (NCI)
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT02923739
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Ovari...
Ovarian Adenoca...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Bevacizumab
Emactuzumab
Laboratory Biom...
Paclitaxel
Pharmacological...
18 Years - M.D. Anderson Cancer Center
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial CancerNCT05950464
Endometrial Car...
Endometrial Cle...
Endometrial End...
Endometrial Low...
Ovarian Clear C...
Ovarian Endomet...
Ovarian High Gr...
Ovarian Low Gra...
Platinum-Resist...
BET Bromodomain...
Biopsy
Biospecimen Col...
Computed Tomogr...
Electrocardiogr...
Magnetic Resona...
Tuvusertib
X-Ray Imaging
18 Years - National Cancer Institute (NCI)
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube CancerNCT00108745
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Clinical Observ...
Laboratory Biom...
Paclitaxel
Paclitaxel Poli...
Quality-of-Life...
- GOG Foundation
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube CancerNCT02068794
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Ovari...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Laboratory Biom...
Mesenchymal Ste...
Oncolytic Measl...
18 Years - Mayo Clinic
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerNCT00888615
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Elesclomol Sodi...
Paclitaxel
18 Years - GOG Foundation
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT02315430
Fallopian Tube ...
Ovarian Clear C...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Cabozantinib S-...
Laboratory Biom...
18 Years - National Cancer Institute (NCI)
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerNCT01097746
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
FIGO Stage III ...
FIGO Stage IIIA...
FIGO Stage IIIA...
FIGO Stage IIIA...
FIGO Stage IIIA...
FIGO Stage IIIA...
FIGO Stage IIIB...
FIGO Stage IIIC...
FIGO Stage IVA ...
FIGO Stage IVB ...
Malignant Ovari...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Primary Periton...
Bevacizumab
Carboplatin
Paclitaxel
18 Years - M.D. Anderson Cancer Center
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)NCT03648489
Ovarian Cancer
Ovarian Neoplas...
Ovarian Carcino...
Ovarian Serous ...
Ovarian Endomet...
Ovarian Clear C...
Fallopian Tube ...
Fallopian Tube ...
Primary Periton...
Primary Periton...
Paclitaxel
TAK228
18 Years - Imperial College London
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerNCT05231122
Ovarian Clear C...
Platinum-Sensit...
Recurrent Endom...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Plati...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Anti-CD40 Agoni...
Bevacizumab
Pembrolizumab
Quality-of-Life...
Questionnaire A...
18 Years - Roswell Park Cancer Institute
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerNCT01504126
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Undiffe...
Primary Periton...
Stage II Fallop...
Stage II Ovaria...
Stage IIA Fallo...
Stage IIA Ovari...
Stage IIB Fallo...
Stage IIB Ovari...
Stage IIC Fallo...
Stage IIC Ovari...
Stage III Fallo...
Stage III Ovari...
Stage III Prima...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Chemotherapy
Propranolol Hyd...
Quality-of-Life...
Therapeutic Con...
18 Years - M.D. Anderson Cancer Center
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerNCT00262847
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Ovari...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Serous ...
Ovarian Transit...
Primary Periton...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Undifferentiate...
Undifferentiate...
Bevacizumab
Carboplatin
Laboratory Biom...
Paclitaxel
Placebo
Quality-of-Life...
18 Years - National Cancer Institute (NCI)
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerNCT05226507
Advanced Solid ...
Ovarian Cancer
Ovarian Clear C...
Ovarian Clear C...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Endomet...
ARID1A Gene Mut...
NXP800
18 Years - Nuvectis Pharma, Inc.
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT00719303
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Ovari...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Primary Periton...
Stage IIA Fallo...
Stage IIA Ovari...
Stage IIB Fallo...
Stage IIB Ovari...
Stage IIC Fallo...
Stage IIC Ovari...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Undifferentiate...
Undifferentiate...
Behavioral Diet...
Compliance Moni...
Counseling
Educational Int...
Exercise Interv...
Laboratory Biom...
Quality-of-Life...
Questionnaire A...
18 Years - GOG Foundation
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerNCT02502266
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Cediranib
Cediranib Malea...
Computed Tomogr...
Magnetic Resona...
Olaparib
Paclitaxel
Pegylated Lipos...
Questionnaire A...
Topotecan
Topotecan Hydro...
18 Years - National Cancer Institute (NCI)
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT02923739
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Ovari...
Ovarian Adenoca...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Bevacizumab
Emactuzumab
Laboratory Biom...
Paclitaxel
Pharmacological...
18 Years - M.D. Anderson Cancer Center
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerNCT05231122
Ovarian Clear C...
Platinum-Sensit...
Recurrent Endom...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Plati...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Anti-CD40 Agoni...
Bevacizumab
Pembrolizumab
Quality-of-Life...
Questionnaire A...
18 Years - Roswell Park Cancer Institute
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerNCT01097746
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
FIGO Stage III ...
FIGO Stage IIIA...
FIGO Stage IIIA...
FIGO Stage IIIA...
FIGO Stage IIIA...
FIGO Stage IIIA...
FIGO Stage IIIB...
FIGO Stage IIIC...
FIGO Stage IVA ...
FIGO Stage IVB ...
Malignant Ovari...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Primary Periton...
Bevacizumab
Carboplatin
Paclitaxel
18 Years - M.D. Anderson Cancer Center
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerNCT00565851
Clear Cell Aden...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Mucinous Adenoc...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Undifferentiate...
Bevacizumab
Carboplatin
Docetaxel
Gemcitabine Hyd...
Laboratory Biom...
Paclitaxel
Quality-of-Life...
18 Years - National Cancer Institute (NCI)
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant EffusionNCT04919629
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Serous ...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Bevacizumab
Biopsy
Biospecimen Col...
Pegcetacoplan
Pembrolizumab
Questionnaire A...
18 Years - Roswell Park Cancer Institute
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE TrialNCT04575935
Advanced Ovaria...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Serous ...
Ovarian Transit...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Stage IVA Fallo...
Stage IVA Ovari...
Stage IVA Prima...
Stage IVB Fallo...
Stage IVB Ovari...
Stage IVB Prima...
Chemotherapy
Laparotomy
Minimally Invas...
Quality-of-Life...
Questionnaire A...
18 Years - M.D. Anderson Cancer Center
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)NCT03648489
Ovarian Cancer
Ovarian Neoplas...
Ovarian Carcino...
Ovarian Serous ...
Ovarian Endomet...
Ovarian Clear C...
Fallopian Tube ...
Fallopian Tube ...
Primary Periton...
Primary Periton...
Paclitaxel
TAK228
18 Years - Imperial College London
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal CancerNCT02364713
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Platinum-Resist...
Platinum-Resist...
Platinum-Resist...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Bevacizumab
Gemcitabine Hyd...
Laboratory Biom...
Oncolytic Measl...
Paclitaxel
Pegylated Lipos...
Quality-of-Life...
Topotecan Hydro...
18 Years - Mayo Clinic
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerNCT01504126
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Undiffe...
Primary Periton...
Stage II Fallop...
Stage II Ovaria...
Stage IIA Fallo...
Stage IIA Ovari...
Stage IIB Fallo...
Stage IIB Ovari...
Stage IIC Fallo...
Stage IIC Ovari...
Stage III Fallo...
Stage III Ovari...
Stage III Prima...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Chemotherapy
Propranolol Hyd...
Quality-of-Life...
Therapeutic Con...
18 Years - M.D. Anderson Cancer Center
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerNCT01097746
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
FIGO Stage III ...
FIGO Stage IIIA...
FIGO Stage IIIA...
FIGO Stage IIIA...
FIGO Stage IIIA...
FIGO Stage IIIA...
FIGO Stage IIIB...
FIGO Stage IIIC...
FIGO Stage IVA ...
FIGO Stage IVB ...
Malignant Ovari...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Primary Periton...
Bevacizumab
Carboplatin
Paclitaxel
18 Years - M.D. Anderson Cancer Center
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal CancerNCT02364713
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Platinum-Resist...
Platinum-Resist...
Platinum-Resist...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Bevacizumab
Gemcitabine Hyd...
Laboratory Biom...
Oncolytic Measl...
Paclitaxel
Pegylated Lipos...
Quality-of-Life...
Topotecan Hydro...
18 Years - Mayo Clinic
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerNCT05231122
Ovarian Clear C...
Platinum-Sensit...
Recurrent Endom...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Plati...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Anti-CD40 Agoni...
Bevacizumab
Pembrolizumab
Quality-of-Life...
Questionnaire A...
18 Years - Roswell Park Cancer Institute
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant EffusionNCT04919629
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Serous ...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Bevacizumab
Biopsy
Biospecimen Col...
Pegcetacoplan
Pembrolizumab
Questionnaire A...
18 Years - Roswell Park Cancer Institute
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerNCT00888615
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Elesclomol Sodi...
Paclitaxel
18 Years - GOG Foundation
Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian CancerNCT00979992
Ovarian Clear C...
Recurrent Ovari...
Laboratory Biom...
Sunitinib Malat...
18 Years - National Cancer Institute (NCI)
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersNCT02020707
Cervical Adenoc...
Cervical Adenos...
Cervical Adenos...
Cervical Carcin...
Cervical Squamo...
Clinical Stage ...
Endometrial Ade...
Endometrial Cle...
Endometrial End...
Endometrial Mix...
Endometrial Muc...
Endometrial Ser...
Endometrial Und...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Femal...
Malignant Ovari...
Malignant Ovari...
Malignant Ovari...
Malignant Ovari...
Malignant Perit...
Malignant Solid...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Ovarian High Gr...
Ovarian Mucinou...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Platinum-Resist...
Platinum-Resist...
Platinum-Resist...
Platinum-Sensit...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Unresectable Me...
Uterine Corpus ...
Bevacizumab
Laboratory Biom...
Nab-paclitaxel
Pharmacological...
18 Years - Mayo Clinic
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial CancerNCT05950464
Endometrial Car...
Endometrial Cle...
Endometrial End...
Endometrial Low...
Ovarian Clear C...
Ovarian Endomet...
Ovarian High Gr...
Ovarian Low Gra...
Platinum-Resist...
BET Bromodomain...
Biopsy
Biospecimen Col...
Computed Tomogr...
Electrocardiogr...
Magnetic Resona...
Tuvusertib
X-Ray Imaging
18 Years - National Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: